Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.

Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA, Ketterling RP, Pardanani A, Tefferi A.

Leukemia. 2012 Jan;26(1):101-5. doi: 10.1038/leu.2011.298. Epub 2011 Oct 28.

PMID:
22033490
2.

[Relationship between clinical characteristics and myelodysplastic syndrome patients with isocitrate dehydrogenase gene mutations].

Tong HY, Hu C, Yu MX, Ma QL, Chen FF, Ye L, Wei JY, Xu GX, Mao LP, Li Y, Jin J.

Zhonghua Yi Xue Za Zhi. 2013 Oct 29;93(40):3180-4. Chinese.

PMID:
24405536
3.

IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.

Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, Yang J, Wang CZ, Chai HY, Qian Z, Xiao GF, Xu WR.

Ann Hematol. 2012 Apr;91(4):519-25. doi: 10.1007/s00277-011-1352-7. Epub 2011 Oct 14.

PMID:
21997850
4.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

PMID:
20567020
5.

[Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].

Jia ZX, Zhou M, Chao HY, Lu XZ, Zhang R, Cen L, Xiao R, Jiang NK.

Zhonghua Xue Ye Xue Za Zhi. 2012 May;33(5):397-401. Chinese.

PMID:
22781800
6.

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.

Chotirat S, Thongnoppakhun W, Promsuwicha O, Boonthimat C, Auewarakul CU.

J Hematol Oncol. 2012 Mar 7;5:5. doi: 10.1186/1756-8722-5-5.

7.

WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations.

Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Holtan SG, Pardanani A, Knudson RA, Ketterling RP, Chen D, Hoyer JD, Hanson CA, Tefferi A.

Leukemia. 2010 Jul;24(7):1283-9. doi: 10.1038/leu.2010.105. Epub 2010 May 20.

8.

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, Wichmann M, Göhring G, Schumann C, Bug G, Ottmann O, Hofmann WK, Schlegelberger B, Ganser A, Heuser M.

Haematologica. 2010 Oct;95(10):1668-74. doi: 10.3324/haematol.2010.025494. Epub 2010 May 21.

9.

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

Lin TL, Nagata Y, Kao HW, Sanada M, Okuno Y, Huang CF, Liang DC, Kuo MC, Lai CL, Lee EH, Shih YS, Tanaka H, Shiraishi Y, Chiba K, Lin TH, Wu JH, Miyano S, Ogawa S, Shih LY.

Haematologica. 2014 Jan;99(1):28-36. doi: 10.3324/haematol.2013.091249. Epub 2013 Aug 30.

10.

IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders.

Zou Y, Zeng Y, Zhang DF, Zou SH, Cheng YF, Yao YG.

Biochem Biophys Res Commun. 2010 Nov 12;402(2):378-83. doi: 10.1016/j.bbrc.2010.10.038. Epub 2010 Oct 12.

PMID:
20946881
11.

Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.

Jin J, Hu C, Yu M, Chen F, Ye L, Yin X, Zhuang Z, Tong H.

PLoS One. 2014 Jun 17;9(6):e100206. doi: 10.1371/journal.pone.0100206. eCollection 2014.

12.

Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.

Rosati S, Mick R, Xu F, Stonys E, Le Beau MM, Larson R, Vardiman JW.

Leukemia. 1996 Jan;10(1):20-6.

PMID:
8558932
13.

Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.

Damm F, Thol F, Hollink I, Zimmermann M, Reinhardt K, van den Heuvel-Eibrink MM, Zwaan CM, de Haas V, Creutzig U, Klusmann JH, Krauter J, Heuser M, Ganser A, Reinhardt D, Thiede C.

Leukemia. 2011 Nov;25(11):1704-10. doi: 10.1038/leu.2011.142. Epub 2011 Jun 7.

PMID:
21647152
14.

Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.

Koszarska M, Bors A, Feczko A, Meggyesi N, Batai A, Csomor J, Adam E, Kozma A, Orban TI, Lovas N, Sipos A, Karaszi E, Dolgos J, Fekete S, Reichardt J, Lehoczky E, Masszi T, Tordai A, Andrikovics H.

Leuk Lymphoma. 2013 May;54(5):1028-35. doi: 10.3109/10428194.2012.736981. Epub 2012 Nov 6.

PMID:
23039322
15.

Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.

Chotirat S, Thongnoppakhun W, Wanachiwanawin W, Auewarakul CU.

Blood Cells Mol Dis. 2015 Mar;54(3):286-91. doi: 10.1016/j.bcmd.2014.11.017. Epub 2014 Nov 26.

PMID:
25486927
16.

[Clinical significance of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].

Mi RH, Lu XD, Wei XD, Fan RH, Yin QS, Hu JY, Wang Q, Song YP.

Zhonghua Xue Ye Xue Za Zhi. 2011 Sep;32(9):610-3. Chinese.

PMID:
22338155
17.

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Löwenberg B, Valk PJ.

Blood. 2010 Sep 23;116(12):2122-6. doi: 10.1182/blood-2009-11-250878. Epub 2010 Jun 10.

18.

Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group.

Nomdedéu J, Hoyos M, Carricondo M, Esteve J, Bussaglia E, Estivill C, Ribera JM, Duarte R, Salamero O, Gallardo D, Pedro C, Aventin A, Brunet S, Sierra J.

Leuk Res. 2012 Aug;36(8):990-7. doi: 10.1016/j.leukres.2012.03.019. Epub 2012 Apr 19.

PMID:
22520341
19.

Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis.

Zhou KG, Jiang LJ, Shang Z, Wang J, Huang L, Zhou JF.

Leuk Lymphoma. 2012 Dec;53(12):2423-9. doi: 10.3109/10428194.2012.695359. Epub 2012 Jun 18.

PMID:
22616558
20.

Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.

Aref S, Kamel Areida el S, Abdel Aaal MF, Adam OM, El-Ghonemy MS, El-Baiomy MA, Zeid TA.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):550-5. doi: 10.1016/j.clml.2015.05.009. Epub 2015 Jun 6.

PMID:
26189213

Supplemental Content

Support Center